IL299223A - Use of trans-[tetrachlorobis(1H-indazole)rotonate(III)] for cancer treatment - Google Patents

Use of trans-[tetrachlorobis(1H-indazole)rotonate(III)] for cancer treatment

Info

Publication number
IL299223A
IL299223A IL299223A IL29922322A IL299223A IL 299223 A IL299223 A IL 299223A IL 299223 A IL299223 A IL 299223A IL 29922322 A IL29922322 A IL 29922322A IL 299223 A IL299223 A IL 299223A
Authority
IL
Israel
Prior art keywords
administered
patient
pharmaceutically acceptable
use according
acceptable composition
Prior art date
Application number
IL299223A
Other languages
English (en)
Hebrew (he)
Original Assignee
Intezyne Tech
Bold Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intezyne Tech, Bold Therapeutics Inc filed Critical Intezyne Tech
Publication of IL299223A publication Critical patent/IL299223A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
IL299223A 2016-03-01 2017-03-01 Use of trans-[tetrachlorobis(1H-indazole)rotonate(III)] for cancer treatment IL299223A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662301786P 2016-03-01 2016-03-01
PCT/US2017/020209 WO2017151775A1 (en) 2016-03-01 2017-03-01 Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL299223A true IL299223A (en) 2023-02-01

Family

ID=59744351

Family Applications (2)

Application Number Title Priority Date Filing Date
IL299223A IL299223A (en) 2016-03-01 2017-03-01 Use of trans-[tetrachlorobis(1H-indazole)rotonate(III)] for cancer treatment
IL261384A IL261384B2 (en) 2016-03-01 2018-08-26 Use of trans-[tetrachlorobis(h1-indazole)rotenate(iii)] for cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL261384A IL261384B2 (en) 2016-03-01 2018-08-26 Use of trans-[tetrachlorobis(h1-indazole)rotenate(iii)] for cancer treatment

Country Status (8)

Country Link
US (4) US10821095B2 (cg-RX-API-DMAC10.html)
EP (1) EP3423055B1 (cg-RX-API-DMAC10.html)
JP (3) JP6997919B2 (cg-RX-API-DMAC10.html)
KR (2) KR102413412B1 (cg-RX-API-DMAC10.html)
CN (1) CN109195600A (cg-RX-API-DMAC10.html)
AU (1) AU2017227705A1 (cg-RX-API-DMAC10.html)
IL (2) IL299223A (cg-RX-API-DMAC10.html)
WO (2) WO2017151762A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299223A (en) * 2016-03-01 2023-02-01 Intezyne Tech Use of trans-[tetrachlorobis(1H-indazole)rotonate(III)] for cancer treatment
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US20230024119A1 (en) * 2019-12-05 2023-01-26 Bold Therapeutics, Inc. Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
US11730750B2 (en) 2020-02-17 2023-08-22 University Of Kentucky Research Foundation Drugs for GRP78 cell surface translocation and Par-4 secretion
WO2021195763A1 (en) * 2020-03-30 2021-10-07 Bold Therapeutics Inc. Antiviral ruthenate(iii) therapeutics
KR20240091105A (ko) * 2021-10-28 2024-06-21 볼드 테라퓨틱스 인코포레이티드 프로테아좀 억제제 내성을 개선시키기 위한 나트륨 트랜스-[테트라클로리도비스(1h-인다졸)루테네이트(iii)]의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2441262T3 (es) 2007-06-11 2014-02-03 Niiki Pharma Inc. Método de fabricación de un complejo de rutenio
WO2012012305A2 (en) 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex
JP6116481B2 (ja) * 2010-10-25 2017-04-19 ニーキ ファーマ インコーポレイテッド 神経内分泌腫瘍を治療する方法
EP3183269A2 (en) * 2014-08-22 2017-06-28 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
IL299223A (en) * 2016-03-01 2023-02-01 Intezyne Tech Use of trans-[tetrachlorobis(1H-indazole)rotonate(III)] for cancer treatment

Also Published As

Publication number Publication date
EP3423055B1 (en) 2026-07-08
US10821095B2 (en) 2020-11-03
AU2017227705A1 (en) 2018-10-18
EP3423055A1 (en) 2019-01-09
US20240091196A1 (en) 2024-03-21
KR102413412B1 (ko) 2022-06-28
JP7513574B2 (ja) 2024-07-09
WO2017151762A1 (en) 2017-09-08
IL261384B1 (en) 2023-01-01
KR20180130509A (ko) 2018-12-07
JP6997919B2 (ja) 2022-01-18
US20210085647A1 (en) 2021-03-25
AU2017227705A9 (en) 2018-12-20
WO2017151775A1 (en) 2017-09-08
IL261384B2 (en) 2023-05-01
EP3423055A4 (en) 2019-10-16
JP2019507166A (ja) 2019-03-14
US20190038601A1 (en) 2019-02-07
US20250387370A1 (en) 2025-12-25
KR20220075450A (ko) 2022-06-08
CN109195600A (zh) 2019-01-11
JP2021167360A (ja) 2021-10-21
WO2017151775A9 (en) 2018-09-13
JP2023024618A (ja) 2023-02-16
IL261384A (en) 2018-10-31
US11633380B2 (en) 2023-04-25

Similar Documents

Publication Publication Date Title
US11633380B2 (en) Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer
Osada et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations
Cao et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells
Li et al. Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma
Fu et al. Combination foretinib and anti-PD-1 antibody immunotherapy for colorectal carcinoma
Zhuang et al. Solasodine inhibits human colorectal cancer cells through suppression of the AKT/glycogen synthase kinase‐3β/β‐catenin pathway
Xu et al. The role of macrophage polarization in ovarian cancer: from molecular mechanism to therapeutic potentials
Wang et al. Leucovorin enhances the anti-cancer effect of bortezomib in colorectal cancer cells
Lee et al. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer
Yang et al. Isogambogenic acid induces apoptosis-independent autophagic cell death in human non-small-cell lung carcinoma cells
Cavalloni et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas
Chen et al. Synergetic impact of combined navoximod with cisplatin mitigates chemo-immune resistance via blockading IDO1+ CAFs-secreted Kyn/AhR/IL-6 and pol ζ-prevented CIN in human oral squamous cell carcinoma
Zhang et al. A novel mechanism of lung cancer inhibition by methionine enkephalin through remodeling the immune status of the tumor microenvironment
Xia et al. Cisatracurium regulates the CXCR4/let-7a-5p axis to inhibit colorectal cancer progression by suppressing TGF-β/SMAD2/3 signalling
Guo et al. IL-6 regulates epithelial ovarian cancer EMT, invasion, and metastasis by modulating Let-7c and miR-200c through the STAT3/HIF-1α pathway
CN114126652A (zh) 抗肿瘤剂和配合剂
Chen et al. Breakdown of chemo-immune resistance by a TDO2-targeted Pt (IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability
Xiu et al. Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFβ and Hedgehog signal pathway
Waddell et al. VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis
Khan et al. Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression
Chen et al. A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib
Singhal et al. Novel compound 1, 3-bis (3, 5-dichlorophenyl) urea inhibits lung cancer progression
Ling et al. Dihydroartemisinin inhibits NSCLC by targeting MDM2/c-Myc axis independent of p53
Dong Investigating Novel Inhibitors of Epithelial–Mesenchymal Transition (EMT) and Cancer Stem Cells (CSCs) in Pancreatic Cancer
CN120585840A (zh) 一种抑制TRIM25和HIF-1α结合的化合物在制备治疗肿瘤药物中的应用